Skip to main content

Advertisement

SpringerLink
Log in

Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease

  • Sarcoma (SH Okuno, Section Editor)
  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Treatment for osteosarcoma, the most common malignant tumor of bone in children and adolescents, has not changed in decades. Treatment is multimodal, employing neoadjuvant chemotherapy followed by aggressive and complete surgical resection to achieve negative margins and a prolonged course of adjuvant chemotherapy. The primary tumor is usually successfully managed via surgery, but micrometastases are likely present in most patients at diagnosis. Death is the result of tumor recurrence in the lungs or more rarely in other bones despite aggressive treatment regimens and is likely attributable to innate resistance to chemotherapy. Better therapies are desperately needed. The three most active agents—high-dose methotrexate, doxorubicin, and cisplatin—commonly referred to as “MAP,” form the backbone of therapy. After 2 cycles of MAP, surgical resection is performed of all sites of disease if possible. Histologic response following neoadjuvant chemotherapy is prognostic in non-metastatic osteosarcoma, but augmentation of adjuvant therapy for poor responders with additional agents (ifosfamide, etoposide) has not improved outcome. Inclusion of immunotherapy into treatment regimens is promising. Specifically, liposome-encapsulated muramyl tripeptide phosphatidylethanolamine (L-MTP-PE), a macrophage and monocyte activator, improved 10-year overall survival for patients with localized disease, with a similar pattern of response in patients with metastatic disease. L-MTP-PE (mifamurtide) is approved and in widespread use in Europe and elsewhere but has not been approved for use by the Federal Drug Administration in the USA. Identifying novel targeted therapies to improve outcomes for patients with osteosarcoma remains an area of active research.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

Paper of particular interest, published recently, have been highlighted as:• Of importance •• Of major importance

  1. Gurney JG, Swensen AR, Bultreys M: Malignant bone tumors, in Ries LAG, Smith MA, Gurney JG, Linet M, Tamra T, Young JL, Bunin GR (eds). Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975–1995, National Cancer Institue, SEER Program. NIH Pub. No. 99–4649. Bethesda, MD, 1999

  2. Fuchs B, Pritchard DJ. Etiology of osteosarcoma. Clin Orthop Relat Res. 2002;397:40–52.

    Article  Google Scholar 

  3. Geller DS, Gorlick R. Osteosarcoma: a review of diagnosis, management, and treatment strategies. Clin Adv Hematol Oncol. 2010;8:705–18.

    PubMed  Google Scholar 

  4. Marina N, Gebhardt M, Teot L, Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist. 2004;9:422–41.

    Article  PubMed  Google Scholar 

  5. Meyers PA, Gorlick R. Osteosarcoma. Pediatr Clin N Am. 1997;44:973–89.

    Article  CAS  Google Scholar 

  6. Kaste SC, Pratt CB, Cain AM, Jones-Wallace DJ, Rao BN. Metastases detected at the time of diagnosis of primary pediatric extremity osteosarcoma at diagnosis: imaging features. Cancer. 1999;86:1602–8.

    Article  CAS  PubMed  Google Scholar 

  7. Meyers PA. Systemic therapy for osteosarcoma and Ewing sarcoma. 2015 ASCO Annual Meeting Educational Book: 2015

  8. Anninga JK, Gelberblom H, Fiocco M, Kroep JR, Taminiau AH, Hogendoom PC, Egeler RM. Chemotherapeutic adjuvant treatment for osteosarcoma: where do we stand? Eur J Cancer. 2011;47:2431–45.

    Article  CAS  PubMed  Google Scholar 

  9. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol. 2002;20:776–90.

    Article  PubMed  Google Scholar 

  10. • Meyers PA, Schwartz CL, Krailo M, Kleinerman ES, Betcher D, Bernstein ML, et al. Osteosarcoma: a randomized, prospective, trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23:2004–11. Large randomized clinical trial showing a trend toward EFS with the addition of L-MTP-PE for patients with localized osteosarcoma.

    Article  CAS  PubMed  Google Scholar 

  11. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002;20:426–33.

    Article  CAS  PubMed  Google Scholar 

  12. Kempf-Bielack B, Bielack SS, Jürgens H, Branscheid D, Berdel WE, Exner GU, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the cooperative osteosarcoma study group. J Clin Oncol. 2005;23:559–68.

    Article  PubMed  Google Scholar 

  13. Ferrari S, Bacci G, Picci P, Mercuri M, Briccoli A, Pinto D, et al. Long-term follow-up and post-relapse survival in patients with non-metastatic osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Ann Oncol. 1997;8:765–71.

    Article  CAS  PubMed  Google Scholar 

  14. Bishop MW, Cheng Y, Krailo MD, Meyers PA, Provisor AJ, Schwartz CL, et al. Assessing the prognostic significance of histologic response in osteosarcoma: a comparison of outcomes on CCG-782 and INT0133—a report from the Children’s Oncology Group Bone Tumor Committee. Pediatr Blood Cancer. 2016;63:1737–43.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Goorin AM, Harris MB, Bernstein M, Ferguson W, Devidas M, Siegal GP, et al. Phase II/III trial of etoposide and high-dose ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. J Clin Oncol. 2002;20:426–33.

    Article  CAS  PubMed  Google Scholar 

  16. •• Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krail M, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomized controlled trial. Lancet Oncol. 2016;17:1396–408. Large international randomized prospective clinical trial showing no difference in EFS for patients who achieve poor necrosis with the addition of ifosfamide and etoposide.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Meyers PA and Chou AJ. Muramyl tripeptide-phosphatidyl ethanolamine encapsulated in liposomes (L-MTP-PE) in the treatment of osteosarcoma. In: Kleinerman ES, editor. Current Advances in Osteosarcoma, Advances in Experimental Medicine and Biology. Springer International Publishing; 2014.

  18. Chou AJ, Kleinerman ES, Krailo MD, Chen Z, Betcher DL, Healey JH, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer. 2009;115:5339–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Bishop MW, Janeway KA, Gorlick R. Future directions in the treatment of osteosarcoma. Curr Opin Pediatr. 2016;28:26–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Luetke A, Meyers PA, Lewis L, Juergens H. Osteosarcoma treatment: where do we stand? A state of the art review. Cancer Treat Rev. 2014;40:523–32.

    Article  PubMed  Google Scholar 

  21. Daw NC, Neel MD, Rao BN, Billups CA, Wu J, Jenkins JJ, et al. Frontline treatment of localized osteosarcoma without methotrexate: results of the St. Jude Children’s Research Hospital OS99 Trial. Cancer. 2011;117:2770–8.

    Article  PubMed  PubMed Central  Google Scholar 

  22. Assi H, Missenard G, Terrier P, Le Pechoux C, Bonvalot S, Vanel D, et al. Intensive induction chemotherapy without methotrexate in adult patients with localized osteosarcoma: results of the Institut Gustave-Roussy phase II trial. Curr Oncol. 2010;17:23–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Meyers PA, Heller G, Healey J, Huvos A, Lane J, Marcove R, et al. Chemotherapy for nonmetastatic osteogenic sarcoma: the memorial Sloan-Kettering experience. J Clin Oncol. 1992;1:5–15.

    Article  Google Scholar 

  24. Imran H, Enders F, Krailo M, Sim F, Okuno S, Hawkins D, et al. Effect of time to resumption of chemotherapy after definitive surgery on prognosis for non-metastatic osteosarcoma. J Bone Joint Surg Am. 2009;91:604–12.

    Article  PubMed  PubMed Central  Google Scholar 

  25. • Janeway KA, Grier HE. Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects. Lancet Oncol. 2010;11:670–8. Review of acute and long term toxicities associated with osteosarcoma treatment.

    Article  PubMed  Google Scholar 

  26. Widemann BC, Balis FM, Kempf-Bielack B, Bielack S, Pratt CB, Ferrari S, et al. High-dose methotrexate-induced nephrotoxicity in patients with osteosarcoma. Cancer. 2004;100:2222–32.

    Article  CAS  PubMed  Google Scholar 

  27. Lajer HJ, Daugaard G. Cisplatin and hypomagnesemia. Cancer Treat Rev. 1999;25:47–58.

    Article  CAS  PubMed  Google Scholar 

  28. Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, Colan SD. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23:2629–36.

    Article  CAS  PubMed  Google Scholar 

  29. Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14:362–72.

    Article  CAS  PubMed  Google Scholar 

  30. Schwartz CL, Wexler LH, Krailo MD, Teot LA, Devidas M, Steinherz LJ, et al. Intensified chemotherapy with dexrazoxane cardioprotection in newly diagnosed nonmetastatic osteosarcoma: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2016;63:54–61.

    Article  CAS  PubMed  Google Scholar 

  31. Volkova M, Russell 3rd R. Anthracycline cardiotoxicity: prevalence, pathogenesis and treatment. Curr Cardiol Rev. 2011;7:214–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Deng S, Yan T, Jendry C, Nemecek A, Vincetic M, Gӧdtel-Armbrust U, Wojnowski L. Dexrazoxane may prevent doxorubicin-induced damage via depleting both topoisomerase II isoforms. BMC Cancer. 2014;14:1–11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Longhi A, Ferrari S, Tamburini A, Luksch R, Fagioli F, Bacci G, Ferrari C. Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian sarcoma group experience (1983–2006). Cancer. 2012;118:5050–9.

    Article  PubMed  Google Scholar 

  34. • Meyers PA, Schwartz CL, Krailo MD, Healey JH, Bernstein ML, Betcher D, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:633–8. Follow up report to INT-0133 with matured data showing an improvement in overall survival with the addition of L-MTP-PE to chemotherapy for localized osteosarcoma.

    Article  CAS  PubMed  Google Scholar 

  35. Sukhvinder J, Ralston S, Knight C. Mifamurtide for high-grade, resectable, nonmetastatic osteosarcoma following surgical resection: a cost-effectiveness analysis. Value Health. 2013;16:1123–32.

    Article  Google Scholar 

  36. Brosa M, García del Muro X, Mora J, Villacampa A, Pozo-Rubio T, Cubells L, Montoto C. Orphan drugs revisited: cost-effectiveness analysis of the addition of mifurmatide to the conventional treatment of osteosarcoma. Expert Rev Pharmacoecon Outcomes Res. 2015;15:331–40.

    Article  PubMed  Google Scholar 

  37. •• Bielack SS, Smeland S, Whelan JS, Marina N, Jovic G, Hook JM, et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015;33:2279–87. Results of large, randomized, international, prospective clinical trial showing no improvement in EFS for patients with good necrosis following definitive surgery with the addition of interferon maintenance therapy to standard MAP.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Whelan J, Patterson D, Perisoglou M, Bielack S, Marina N, Smeland S, Bernstein M. The role of interferons in the treatment of osteosarcoma. Pediatr Blood Cancer. 2010;54:350–4.

    Article  PubMed  Google Scholar 

  39. Müller CR, Smeland S, Bauer HC, Saeter G, Strander H. Interferon-alpha as the only adjuvant treatment in high-grade osteosarcoma: long term results of the Karolinska Hospital series. Acta Oncol. 2005;5:475–80.

    Article  Google Scholar 

  40. Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014;2:690–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Lussier DM, Johnson JL, Hingorani P, Blattman JN. Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma. J Immunother Cancer. 2015;3:1–11.

    Article  Google Scholar 

  42. Branstetter D, Rohrbach K, Huang LY, Soriano R, Tometsko M, Blake M, et al. RANK and RANK ligand expression in primary human osteosarcoma. J Bone Oncol. 2015;4:59–68.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Branstetter D, Nelson SD, Manivel JC, Blay JY, Chawla S, Thomas DM, et al. Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone. Clin Cancer Res. 2012;18:4415–24.

    Article  CAS  PubMed  Google Scholar 

  44. Chawla S, Henshaw R, Seeger L, Choy E, Blay JY, Ferrari S, et al. Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study. Lancet Oncol. 2013;14:901–8.

    Article  CAS  PubMed  Google Scholar 

  45. Roth M, et al. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer. 2014;120:548–54.

    Article  CAS  PubMed  Google Scholar 

  46. Yu A, Gilman AL, Ozkaynak MF, London WB, Kreissman SG, Chen HX, et al. Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma. N Engl J Med. 2010;363:1324–34.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Kolb EA, Gorlick R, Billups CA, Hawthorne T, Kurmasheva RT, Houghton PJ, Smith MA. Initial testing (stage 1) of glembatumumab vedotin (CDX-011) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2014;61:1816–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Roth M, Barris DM, Piperdi S, Kuo V, Everts S, Geller D, et al. Targeting glycoprotein NMB with antibody-drug conjugate, glembatumumab vedontin, for the treatment of osteosarcoma. Pediatr Blood Cancer. 2016;63:32–8.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, 77030, USA

    Douglas J. Harrison MD, MS & Cindy L. Schwartz MD, MPH

Authors
  1. Douglas J. Harrison MD, MS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Cindy L. Schwartz MD, MPH
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Douglas J. Harrison MD, MS.

Ethics declarations

Conflict of interest

Douglas J. Harrison and Cindy L. Schwartz declare that they have no conflict of interest.

Human and animal rights and informed consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Sarcoma

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Harrison, D.J., Schwartz, C.L. Osteogenic Sarcoma: Systemic Chemotherapy Options for Localized Disease. Curr. Treat. Options in Oncol. 18, 24 (2017). https://doi.org/10.1007/s11864-017-0464-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11864-017-0464-2

Keywords

Search

Navigation